...
首页> 外文期刊>British Journal of Cancer >Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer
【24h】

Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer

机译:增殖相关因子MIB1(Ki-67)和S期对淋巴结阴性乳腺癌的预后影响

获取原文

摘要

MIB1 proliferation rate (MIB1-PR) and total S-phase fraction (SPF) were retrospectively determined in formalin-fixed, paraffin-embedded sections of 90 primary node-negative breast carcinomas. None of the patients had received adjuvant systemic therapy. Median follow-up in patients still alive at the time of analysis was 37.5 months (16-72 months). Immunostaining of Ki-67 antigen was performed using the monoclonal antibody MIB1 and the APAAP technique. An adjacent 50-microm paraffin section was used for flow cytometric S-phase determination. Results were compared to established clinicopathological prognostic factors. MIB1-PR was significantly correlated to grading (P = 0.018); SPF was significantly correlated with tumour size (P = 0.041) and inversely with steroid hormone receptor status (P = 0.03). A significant correlation between MIB1-PR and SPF was found in aneuploid (P = 0.025) but not in diploid tumours (P = 0.164). In univariate analysis, both MIB1-PR (optimized cut-off of 25%) and SPF (optimized cut-off of 8%) were significant prognostic factors for disease-free survival (DFS) (MIB1-PR, P = 0.0224; SPF, P = 0.0028). In multivariate analysis, however, only SPF remained significant; it was the strongest prognostic factor for DFS (P = 0.0073), stronger than MIB1-PR or established clinicopathological prognostic factors. We thus conclude that MIB1-PR and SPF provide additional prognostic information in node-negative breast cancer. However, in our study, flow cytometrically determined SPF had the greater prognostic impact.
机译:在90例原发淋巴结阴性乳腺癌的福尔马林固定石蜡包埋切片中,回顾性确定了MIB1增殖率(MIB1-PR)和总S期分数(SPF)。所有患者均未接受辅助全身治疗。分析时仍存活的患者的中位随访时间为37.5个月(16-72个月)。 Ki-67抗原的免疫染色使用单克隆抗体MIB1和APAAP技术进行。相邻的50微米石蜡切片用于流式细胞术S期测定。将结果与确定的临床病理预后因素进行比较。 MIB1-PR与等级显着相关(P = 0.018); SPF与肿瘤大小显着相关(P = 0.041),与甾体激素受体状态呈负相关(P = 0.03)。在非整倍体中发现MIB1-PR与SPF之间存在显着相关性(P = 0.025),而在二倍体肿瘤中则没有发现(P = 0.164)。在单因素分析中,MIB1-PR(最佳临界值25%)和SPF(最佳临界值8%)都是无病生存期(DFS)的重要预后因素(MIB1-PR,P = 0.0224; SPF ,P = 0.0028)。但是,在多变量分析中,只有SPF保持显着;它是DFS的最强预后因素(P = 0.0073),比MIB1-PR或已建立的临床病理预后因素强。因此,我们得出结论,MIB1-PR和SPF在淋巴结阴性乳腺癌中提供了更多的预后信息。然而,在我们的研究中,流式细胞术确定的SPF对预后的影响更大。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号